{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:54:10Z","timestamp":1792601650739,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5540-5","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T09:03:08Z","timestamp":1554454988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-4963","authenticated-orcid":false,"given":"Carolien M.","family":"Beukhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francien H.","family":"van Nederveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise F.","family":"van Velthuysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda B.","family":"de Rijke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo J.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston J. H.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lideke A. C.","family":"Fr\u00f6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boen L. R.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Edward","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin P.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"issue":"12","key":"5540_CR1","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","volume":"83","author":"SA Hundahl","year":"1998","unstructured":"Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638\u201348.","journal-title":"Cancer"},{"issue":"6","key":"5540_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association. 2015;25(6):567\u2013610.","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"issue":"29","key":"5540_CR3","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639\u201346.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5540_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134\u201341.","journal-title":"J Clin Oncol"},{"issue":"6","key":"5540_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s004280100494","volume":"439","author":"M Papotti","year":"2001","unstructured":"Papotti M, Croce S, Bello M, Bongiovanni M, Allia E, Schindler M, Bussolati G. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch. 2001;439(6):787\u201397.","journal-title":"Virchows Arch"},{"issue":"5","key":"5540_CR6","first-page":"2161","volume":"86","author":"MC Zatelli","year":"2001","unstructured":"Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab. 2001;86(5):2161\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5540_CR7","first-page":"567","volume":"64","author":"JC Reubi","year":"1991","unstructured":"Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Investig. 1991;64(4):567\u201373.","journal-title":"Lab Investig"},{"issue":"10","key":"5540_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/apm.12584","volume":"124","author":"M Herac","year":"2016","unstructured":"Herac M, Niederle B, Raderer M, Krebs M, Kaserer K, Koperek O. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. APMIS. 2016;124(10):839\u201345.","journal-title":"APMIS"},{"issue":"1","key":"5540_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-2265.1995.tb02595.x","volume":"42","author":"K Frank-Raue","year":"1995","unstructured":"Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol. 1995;42(1):31\u20137.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"5540_CR10","first-page":"1413","volume":"76","author":"DJ Kwekkeboom","year":"1993","unstructured":"Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, Krenning EP. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76(6):1413\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5540_CR11","first-page":"362","volume":"16","author":"G Treglia","year":"2017","unstructured":"Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens). 2017;16(4):362\u201372.","journal-title":"Hormones (Athens)"},{"issue":"2","key":"5540_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"22 Pt 1","key":"5540_CR13","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","volume":"13","author":"F Iten","year":"2007","unstructured":"Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR, Muller-Brand J, Walter MA. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13(22 Pt 1):6696\u2013702.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5540_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/RLU.0000000000000628","volume":"40","author":"F Vaisman","year":"2015","unstructured":"Vaisman F, de Castro PH, Lopes FP, Kendler DB, Pessoa CH, Bulzico DA, de Carvalho Leal D, Vilhena B, Vaisman M, Carneiro M, et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin Nucl Med. 2015;40(2):123\u20137.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"5540_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"9","key":"5540_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","volume":"52","author":"S Khan","year":"2011","unstructured":"Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52(9):1361\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"5540_CR17","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754\u201362.","journal-title":"J Clin Oncol"},{"issue":"16","key":"5540_CR18","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with Gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324.","journal-title":"Clin Cancer Res"},{"key":"5540_CR19","unstructured":"Institute NC. Common terminology criteria for adverse events v4.0 in: NIH publication. Vol. In: 09\u20137473; 2009."},{"issue":"2","key":"5540_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/snuc.2002.31022","volume":"32","author":"DJ Kwekkeboom","year":"2002","unstructured":"Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32(2):84\u201391.","journal-title":"Semin Nucl Med"},{"key":"5540_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.humpath.2017.11.008","volume":"72","author":"A Kasajima","year":"2018","unstructured":"Kasajima A, Papotti M, Ito W, Brizzi MP, La Salvia A, Rapa I, Tachibana T, Yazdani S, Sasano H, Volante M. High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Hum Pathol. 2018;72:144\u201352.","journal-title":"Hum Pathol"},{"issue":"11","key":"5540_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1089\/thy.2006.16.1163","volume":"16","author":"JW Groot de","year":"2006","unstructured":"de Groot JW, Kema IP, Breukelman H, van der Veer E, Wiggers T, Plukker JT, Wolffenbuttel BH, Links TP. Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2006;16(11):1163\u201370.","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"issue":"3","key":"5540_CR23","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1677\/ERC-10-0024","volume":"17","author":"G Kaltsas","year":"2010","unstructured":"Kaltsas G, Androulakis II, de Herder WW, Grossman AB. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer. 2010;17(3):R173\u201393.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"5540_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/1097-0142(19840115)53:2<278::AID-CNCR2820530216>3.0.CO;2-Z","volume":"53","author":"B Busnardo","year":"1984","unstructured":"Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53(2):278\u201385.","journal-title":"Cancer"},{"issue":"9","key":"5540_CR25","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.22244","volume":"107","author":"S Roman","year":"2006","unstructured":"Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134\u201342.","journal-title":"Cancer"},{"issue":"1","key":"5540_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO;2-3","volume":"85","author":"B Denzler","year":"1999","unstructured":"Denzler B, Reubi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer. 1999;85(1):188\u201398.","journal-title":"Cancer"},{"issue":"6","key":"5540_CR27","doi-asserted-by":"publisher","first-page":"H1815","DOI":"10.1152\/ajpheart.2000.278.6.H1815","volume":"278","author":"SB Curtis","year":"2000","unstructured":"Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN, Buchan AM. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol. 2000;278(6):H1815\u201322.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"23","key":"5540_CR28","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1002\/cncr.28341","volume":"119","author":"K Okuwaki","year":"2013","unstructured":"Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M, et al. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer. 2013;119(23):4094\u2013102.","journal-title":"Cancer"},{"issue":"3","key":"5540_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3892\/ol.2017.5591","volume":"13","author":"Y Wang","year":"2017","unstructured":"Wang Y, Wang W, Jin K, Fang C, Lin Y, Xue L, Feng S, Zhou Z, Shao C, Chen M, et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13(3):1165\u201374.","journal-title":"Oncol Lett"},{"issue":"40","key":"5540_CR30","doi-asserted-by":"publisher","first-page":"e1281","DOI":"10.1097\/MD.0000000000001281","volume":"94","author":"S Mehta","year":"2015","unstructured":"Mehta S, de Reuver PR, Gill P, Andrici J, D'Urso L, Mittal A, Pavlakis N, Clarke S, Samra JS, Gill AJ. Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors. Medicine (Baltimore). 2015;94(40):e1281.","journal-title":"Medicine (Baltimore)"},{"key":"5540_CR31","doi-asserted-by":"crossref","unstructured":"de Vries LH, Lodewijk L, Willems SM, Dreijerink KMA, de Keizer B, van Diest PJ, Schepers A, Bonenkamp HJ, van Engen-van Grunsven I, Kruijff S et al: SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. Endocrine 2018.","DOI":"10.1007\/s12020-018-1706-1"},{"issue":"9","key":"5540_CR32","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, Cumming P, Bartenstein P, Tiling R, Hacker M. 68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349\u201356.","journal-title":"J Nucl Med"},{"issue":"1","key":"5540_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000265561","volume":"91","author":"J Ruf","year":"2010","unstructured":"Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, et al. Impact of multiphase 68Ga-DOTATOC-PET\/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91(1):101\u20139.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"5540_CR34","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and Gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57(6):872\u20138.","journal-title":"J Nucl Med"},{"issue":"5","key":"5540_CR35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2967\/jnumed.115.163865","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, et al. Safety and efficacy of 68Ga-DOTATATE PET\/CT for diagnosis, staging, and treatment Management of Neuroendocrine Tumors. J Nucl Med. 2016;57(5):708\u201314.","journal-title":"J Nucl Med"},{"issue":"9","key":"5540_CR36","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1002\/1097-0142(19871101)60:9<2189::AID-CNCR2820600913>3.0.CO;2-C","volume":"60","author":"JL Baulieu","year":"1987","unstructured":"Baulieu JL, Guilloteau D, Delisle MJ, Perdrisot R, Gardet P, Delepine N, Baulieu F, Dupont JL, Talbot JN, Coutris G, et al. Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer. 1987;60(9):2189\u201394.","journal-title":"Cancer"},{"issue":"4","key":"5540_CR37","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.8156","volume":"11","author":"E Skoura","year":"2013","unstructured":"Skoura E. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11(4):e8156.","journal-title":"Int J Endocrinol Metab"},{"issue":"6","key":"5540_CR38","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1089\/thy.2011.0174","volume":"22","author":"JC Maiza","year":"2012","unstructured":"Maiza JC, Grunenwald S, Otal P, Vezzosi D, Bennet A, Caron P. Use of 131 I-MIBG therapy in MIBG-positive metastatic medullary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association. 2012;22(6):654\u20135.","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"issue":"4","key":"5540_CR39","first-page":"430","volume":"52","author":"MR Castellani","year":"2008","unstructured":"Castellani MR, Seregni E, Maccauro M, Chiesa C, Aliberti G, Orunesu E, Bombardieri E. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging. 2008;52(4):430\u201340.","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5540-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5540-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5540-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T19:08:59Z","timestamp":1585940939000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5540-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5540"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5540-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the Erasmus Medical Center (127.545\/1993\/84) and written informed consent was obtained from participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"325"}}